Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Roundhill NVDA WeeklyPay ETFTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Roundhill NVDA WeeklyPay ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $38.32, while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.

NVDWVRTX
Sector
Income / Options OverlayHealth
52-Week High
$52.59$529.65
52-Week Low
$31.88$376.62
Market Cap
$134.25B
Enterprise Value
$128.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Roundhill NVDA WeeklyPay ETF

NVDW, trading at $38.53, gained 3.21% in the last session with a bullish technical signal driven by moving averages. The stock exhibits strong weekly dividend activity, with recent payouts ranging from $0.13 to $0.48, indicating a focus on income generation. Key resistance lies near $39, while support is established around $36–37.

The outlook hinges on NVDW's ability to sustain its dividend strategy amid market volatility. Risks include payout consistency and reliance on underlying asset performance. Opportunities exist for income-focused investors, but cautious monitoring of technical overbought signals is warranted.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $525.72, up 0.35% on the day, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales guidance, driven by cystic fibrosis drug strength and new product contributions. Profitability remains robust with a 35% net income margin, though the P/E ratio of 30.85 reflects premium valuation.

Outlook is positive with 84% analyst buy ratings and a $534.25 consensus target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of new launches and sustained CF franchise growth, while any clinical or regulatory setbacks could pressure the stock.

Returns comparison

Trailing returns across standard periods

About Roundhill NVDA WeeklyPay ETF

NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.

Read more on NVDW

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX